skip to main content

Prof. Dr. rer. nat. Heike Brötz-Oesterhelt


Interfaculty Institute of Microbiology and Infection Medicine Tübingen (IMIT)
Microbial Bioactive Compounds

Tel:+49 (7071) 29- 74706


Research Interest

Heike Brötz-Oesterheilt's research interests include the molecular mechanisms of new antibiotic lead structures. She is dedicated to the identification of antibiotics with new modes of action to kill multidrug-resistant bacterial pathogens. For example, she discovered that nisin and other lantibiotics use the cell wall precursor lipid II as a docking molecule to form pores in the bacterial membrane and that acyldepsipeptide (ADEP) antibiotics deregulate the bacterial Clp protease.

Website Research Group Brötz-Oesterhelt

About Heike Brötz-Oesterhelt

Heike Brötz-Oesterhelt studied Biology in Bonn, Germany, and obtained her Diploma and PhD degrees in Microbiology. For more than 20 years, she has been working in antibacterial drug discovery in the academic as well as in the pharmaceutical industry setting. After her PhD, she joined the Anti-Infectives Department of Bayer HealthCare in Wuppertal, evaluating novel targets and developing lead structures. She headed project teams in structure optimization campaigns and coordinated all early research activities of the department. In 2006 she co-founded the Biotech company AiCuris. In 2010, she returned to academia as a professor for Pharmaceutical Biology at the University of Düsseldorf, and since 2014 she is full professor for Microbiology at the University of Tübingen heading the Department of Microbial Bioactive Compounds. Currently, she is managing director of the Interfaculty Institute of Microbiology and Infection Medicine, Tübingen, deputy speaker of the partner site Tuebingen within the German Center of Infection Research (DZIF), as well as member of the Internal Advisory Board at DZIF. Heike Brötz-Oesterhelt is deputy spokesperson for the Cluster of Excellence CMFI.

Prizes and Awards

For her work, Heike Brötz-Oesterhelt received, among others, the Clinical Research and Development Publication Award from Pfizer and the Research Innovation Prize from Bayer HealthCare AG.


You can find a list of publications here